Hyperfine, Inc.
NASDAQ:HYPRMedical - Devices
+$0.22 today
- Market cap
- $51.10M
- Beta
- 1.38
- P/E (TTM)
- -4.5
- EPS (TTM)
- -$0.36
Volume 1.16M
Average 0.60M
HYPR Total Liabilities
Everything the company owes to creditors and other parties.
Hyperfine, Inc.NASDAQ: HYPR
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities rises 153.1% from a year ago
Total liabilities stood at $25.98M at the end of Q1 FY2026, up 153.1% from a year earlier and up 82.2% from the prior quarter. Over 3 fiscal years it compounded at +11.3% a year.
Context
- Total liabilities amounted to 43.1% of total assets at the end of Q1 FY2026, up 23.8 pp from a year earlier.
- Total liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +153.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 14.26M USD
- Year-over-year change
- +44.6%
- 4-year CAGR
- -3.2%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 14.26M | +44.6% |
| FY2024 | 2024-12-31 | 9.86M | +0.6% |
| FY2023 | 2023-12-31 | 9.8M | -5.1% |
| FY2022 | 2022-12-31 | 10.33M | -36.4% |
| FY2021 | 2021-12-31 | 16.25M | — |
Total Liabilities vs competitors
How HYPR compares with its peers on the latest reported figures
- HYPR's Mar 2026 total liabilities of $25.98M is the 4th highest of the 7 companies compared; the peer median is $39.02M.
- Its year-over-year change of +153.1% is the highest of 7, against a peer median of +1.2%.
- Total liabilities amounts to 43.1% of total assets for HYPR, versus a peer median of 40.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $74.71M | +0.8% | +75.5% | 144.9% | |
| Mar 2026 | $74.21M | +1.6% | +23.7% | 61.9% | |
| Mar 2026 | $54.77M | +0.2% | +2.3% | 25.0% | |
| Mar 2026 | $25.98M | +153.1% | +11.3% | 43.1% | |
| Mar 2026 | $23.27M | -2.4% | +51.4% | 54.9% | |
| Dec 2025 | $14.1M | +54.6% | -5.2% | 25.1% | |
IMAImageneBio Inc | Mar 2026 | $13.36M | +6.1% | -7.8% | 9.8% |
| Peer median (excluding HYPR) | $39.02M | +1.2% | +13.0% | 40.0% | |
Competitors are the stored peer set for HYPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 188.5M | 118.24M | 75.18M | 37.65M | 35.09M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 644K | 3.13M | 4.13M | 8.31M | 6.52M |
| Inventory | 4.31M | 4.62M | 6.58M | 5.83M | 7.09M |
| Other Current Assets | 2.87M | 2.67M | 3.01M | 1.93M | 2.21M |
| Total Current Assets | 197.49M | 128.66M | 88.91M | 53.71M | 50.91M |
| Property, Plant & Equipment (Net) | 3.75M | 3.25M | 3M | 3.12M | 2.55M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 744K | 0 | 825K | 734K |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 1.24M | 1.4M | 2.29M | 1.24M | 1.07M |
| Total Non-current Assets | 4.99M | 5.39M | 5.29M | 5.19M | 4.35M |
| Total Assets | 202.47M | 134.05M | 94.2M | 58.9M | 55.26M |
| Account Payables | 2.25M | 678K | 1.21M | 1.61M | 4.05M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 730K | 1.38M | 2.07M | 1.49M | 2.5M |
| Other Current Liabilities | 700K | 2.2M | 2.91M | 473K | 1.7M |
| Total Current Liabilities | 15.74M | 8.8M | 8.77M | 8.73M | 11.73M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 510K | 1.53M | 968K | 1.05M | 729K |
| Other Non-current Liabilities | 0 | 0 | 64K | 78K | 1.73M |
| Total Non-current Liabilities | 510K | 1.53M | 1.03M | 1.13M | 2.53M |
| Total Liabilities | 16.25M | 10.33M | 9.8M | 9.86M | 14.26M |
| Common Stock | 7K | 7K | 7K | 7K | 10K |
| Retained Earnings | (136.32M) | (209.48M) | (253.72M) | (294.44M) | (330.02M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 186.23M | 123.72M | 84.4M | 49.04M | 41.01M |
| Total Debt | 0 | 0 | 185K | 269K | 314K |
| Net Debt | (188.5M) | (118.24M) | (75M) | (37.38M) | (34.77M) |
Hyperfine, Inc.
NASDAQ:HYPR
Intrinsic Alpha fair value
Locked
Current Price
$0.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.